AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00097773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin solution for inhalation (TOBI)
Description: Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
Study NCT00097773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin solution for inhalation (TOBI)
Description: Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
Study NCT00097773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
Study NCT00097773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ciprofloxacin
Description: Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
Study NCT01023867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: from 5mg to 10mg, once a day, 12 months
Study NCT03924336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)
Description: Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
Study NCT03924336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD) alone
Description: Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
Study NCT00780819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoleStar N20 intraoperative MRI
Description: low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
Study NCT04032704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: Intravenous (into the vein; IV) infusion
Study NCT04032704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg given by IV on Day 1 of each 21-day cycle
Study NCT01408433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single Embryo Transfer
Description: single embryo transfer of a chromosomally normal embryo
Study NCT01408433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Double embryo transfer
Description: two (2) embryo transfer of untested embryos
Study NCT01186900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided needle aspiration
Description: one time drainage at time of randomization
Study NCT01186900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided needle aspiration
Description: one time drainage at time of randomization
Study NCT01249820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin 200 mg q48h
Description: Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
Study NCT01249820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin 300 mg q72h
Description: Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
Study NCT03388242 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
Study NCT05956730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity (AUD)
Description: Home training of patients with severe low vision managed through audio-guides (AUD).
Study NCT05956730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity (SUP)
Description: Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
Study NCT03975621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
Study NCT00754351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
Study NCT00754351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
Study NCT00754351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
Study NCT00874445 — intervention group
Intervention type: DEVICE
Intervention: ICD/ CRT-D
Description: Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
Study NCT03522051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium silicate based material,
Description: Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
Study NCT04417179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis block
Description: transversus abdominis block
Study NCT04417179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: Erector spinae block
Study NCT04417179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Local Anesthetic used in both blocks
Study NCT04417179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Acuson x300 3-5MHz Ultrasound
Description: Ultrasound used to aid in the blocks
Study NCT01226459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil Topical Foam
Description: Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
Study NCT01226459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Foam
Description: Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
Study NCT03770091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theraworx
Description: Theraworx foam applied to skin and/or compression wrap
Study NCT03770091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo foam
Study NCT03193762 — intervention group
Intervention type: OTHER
Intervention: Anxiety VAS
Description: Anxiety will be measure with a 10-points visual analogic scale (VAS)
Study NCT00571844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
Study NCT00571844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet plus Weight loss
Description: Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
Study NCT03436381 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
Study NCT03366090 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsies during coloscopy
Description: During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
Study NCT00002970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study NCT00002970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT00002970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00002970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study NCT03437564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablet
Study NCT05838079 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Description: Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
Study NCT05712148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell implantation
Description: Suprachoridal mesenchymal spheroidal stem cell implantation
Study NCT05520437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
Study NCT05520437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
Study NCT01693354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mid-dilution HDF
Description: Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
Study NCT01693354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF dialysis
Description: Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
Study NCT00908024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Study NCT00908024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab (Erbitux®)
Description: IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Study NCT03150862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered as specified in the treatment arm
Study NCT03150862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Administered as specified in the treatment arm
Study NCT03150862 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Up to 60 Gy (total) over 6 - 7 weeks
Study NCT05569083 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis of APOE and BDNF genes.
Description: The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
Study NCT05569083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EEG recording
Description: The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
Study NCT05569083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF collection and AD biomarker measurement
Description: The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
Study NCT05569083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological evaluation
Description: For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL).
Study NCT01770470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Chitosan
Description: The product chitosan is contained in a chewing gum formulation
Study NCT04071847 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation (DBS)
Description: Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
Study NCT02984579 — intervention group
Intervention type: DEVICE
Intervention: YD REBA MTB-MDR
Description: Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
Study NCT02984579 — intervention group
Intervention type: DEVICE
Intervention: Hain Genotype MTBDRplus V1
Description: Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
Study NCT02984579 — intervention group
Intervention type: DEVICE
Intervention: Hain Genotype MTBDRplus V2
Description: Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
Study NCT04611971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benlysta
Description: Benlysta injection will be administered subcutaneously.
Study NCT04611971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candin
Description: Candin will be administered intradermally along with NaCl solution.
Study NCT04209036 — intervention group
Intervention type: OTHER
Intervention: 0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)
Description: total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
Study NCT00927654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost (Ventavis)
Description: Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
Study NCT00927654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride solution 0.9 % (placebo)
Description: Twice at day 0 intraoperatively
Study NCT04660513 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Subjects with morbid obesity underwent bariatric surgery
Study NCT03358199 — intervention group
Intervention type: PROCEDURE
Intervention: LOD
Description: Women underwent LOD in the preceding 3 months prior to IVF/ICSI
Study NCT01953575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Impedance
Description: A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.
Study NCT01953575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
Study NCT01953575 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Upper Endoscopy
Description: Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
Study NCT01483716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Study NCT02512133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIGS Hydrus Ivantis
Description: implant of the micro stent in the nasal Schlemm's canal
Study NCT02512133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 360 degrees SLT
Description: Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
Study NCT00685880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy (10% dextrose solution)
Description: Dextrose diluted with sterile water.
Study NCT00685880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
Study NCT05145998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucola
Description: 50 grams of Glucola sugar beverage
Study NCT05145998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole pea meal
Description: Whole cooked peas with spaghetti sauce and a slice of bread.
Study NCT05145998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea flour meal
Description: Pea flour with spaghetti sauce and a slice of bread.
Study NCT05145998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole lentils
Description: Whole cooked lentils with spaghetti sauce and a slice of bread.
Study NCT05145998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lentil flour
Description: Lentil flour with spaghetti sauce and a slice of bread.
Study NCT02349594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven 10%
Description: intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
Study NCT02349594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
Study NCT03609138 — intervention group
Intervention type: DEVICE
Intervention: Spinal Hardware
Description: Pedicle screws and patient specific rods